加味肾气丸联合抗VEGF药物治疗脾肾两虚型糖尿病视网膜病变的效果观察(1)
【摘要】 目的：觀察加味肾气丸联合抗血管内皮生长因子(VEGF)药物治疗脾肾两虚型糖尿病视网膜病变(DR)的效果。方法：选取2018年4月-2019年10月本院收治的86例脾肾两虚型DR患者作为研究对象，依据随机数字表法分成试验组和对照组，各43例。对照组患者采用抗VEGF药物，试验组在对照组基础上加用加味肾气丸。比较治疗前及治疗3个月后两组患者中医症状积分、视力、视网膜黄斑厚度和生化指标[血管内皮生长因子(VEGF)、中性粒细胞活化肽-78(ENA-78)、细胞间黏附分子-1(ICAM-1)]水平变化，比较治疗3个月内两组患者眼部不良事件发生情况。结果：治疗3个月后，两组患者的视物昏花、目睛干涩及倦怠乏力积分和视网膜黄斑厚度、VEGF、ENA-78和ICAM-1水平均较治疗前显著降低，且试验组上述指标均明显低于对照组(P<0.05);两组患者视力较治疗前均显著升高，且试验组明显高于对照组(P<0.05)。两组眼部不良事件发生率比较，差异无统计学意义(字2=0.091，P=0.763)。结论：加味肾气丸联合抗VEGF药物治疗脾肾两虚型DR可获得良好效果，能有效改善患者视力，使视网膜黄斑厚度降低，患者血清生化指标水平随之改善，且眼部不良事件发生率低，可于临床普及应用。
【关键词】 糖尿病视网膜病变 加味肾气丸 血管内皮生长因子 眼部不良事件
[Abstract] Objective： To observe the effect of Jiawei Shenqi Pill combined with anti vascular endothelial growth factor (VEGF) in the treatment of diabetic retinopathy (DR) of spleen-kidney deficiency type. Method： A total of 86 cases of DR with deficiency of both spleen and kidney in our hospital from April 2018 to October 2019 were selected as the research objects， according to the method of random number table， they were divided into experimental group and control group， 43 cases in each group. Patients in the control group were given anti VEGF drugs， while those in the experimental group were given Jiawei Shenqi Pill on the basis of the control group. Before treatment and 3 months after the treatment， the symptom scores， visual acuity， macular thickness and biochemical indexes (VEGF， ENA-78， ICAM-1) of the two groups were observed， the occurrence of ocular adverse events within 3 months of treatment was compared between the two groups. Result： After 3 months of treatment， the scores of blurred vision， dry eye and fatigue， and the levels of macular thickness， VEGF， ENA-78 and ICAM-1 in both groups were significantly lower than those in the control group， and the experimental group above indicators were significantly lower than the control group (P<0.05); visual acuity in both groups was significantly higher than that before treatment， and the experimental group was significantly higher than that of the control group (P<0.05). There was no statistically significant difference in the incidence of ocular adverse events between the two groups (字2=0.091， P=0.763). Conclusion： Jiawei Shenqi Pill combined with anti VEGF drug in the treatment of DR with spleen-kidney deficiency can achieve good results， effectively improve the patient’s vision， reduce the thickness of macular degeneration， and subsequently improve the level of serum biochemical indicators in patients， and the incidence of adverse events in the eyes is low， which can be widely used in clinical practice., http://www.100md.com(余日成)
【关键词】 糖尿病视网膜病变 加味肾气丸 血管内皮生长因子 眼部不良事件
[Abstract] Objective： To observe the effect of Jiawei Shenqi Pill combined with anti vascular endothelial growth factor (VEGF) in the treatment of diabetic retinopathy (DR) of spleen-kidney deficiency type. Method： A total of 86 cases of DR with deficiency of both spleen and kidney in our hospital from April 2018 to October 2019 were selected as the research objects， according to the method of random number table， they were divided into experimental group and control group， 43 cases in each group. Patients in the control group were given anti VEGF drugs， while those in the experimental group were given Jiawei Shenqi Pill on the basis of the control group. Before treatment and 3 months after the treatment， the symptom scores， visual acuity， macular thickness and biochemical indexes (VEGF， ENA-78， ICAM-1) of the two groups were observed， the occurrence of ocular adverse events within 3 months of treatment was compared between the two groups. Result： After 3 months of treatment， the scores of blurred vision， dry eye and fatigue， and the levels of macular thickness， VEGF， ENA-78 and ICAM-1 in both groups were significantly lower than those in the control group， and the experimental group above indicators were significantly lower than the control group (P<0.05); visual acuity in both groups was significantly higher than that before treatment， and the experimental group was significantly higher than that of the control group (P<0.05). There was no statistically significant difference in the incidence of ocular adverse events between the two groups (字2=0.091， P=0.763). Conclusion： Jiawei Shenqi Pill combined with anti VEGF drug in the treatment of DR with spleen-kidney deficiency can achieve good results， effectively improve the patient’s vision， reduce the thickness of macular degeneration， and subsequently improve the level of serum biochemical indicators in patients， and the incidence of adverse events in the eyes is low， which can be widely used in clinical practice., http://www.100md.com(余日成)